Diabetic Macular Edema Treatment
Sponsor: Alimera Sciences
Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema
Purpose: To assess the efficacy of ILUVIEN as baseline therapy in patients with early Diabetic Macular Edema (DME).
Eligibility:
- No prior treatment for DME
- Other protocol-specific inclusion and exclusion criteria may apply
Participants will:
- Have access to new treatment before the general public
- Be compensated for study visit
Principal Investigator: Sonia Dhoot, MD
Sub Investigator: Brian Kim, MD
Neovascular Age-related Macular Treatment
Sponsor: Opthea Ltd.
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Purpose: To evaluate the safety and efficacy of intravitreal OPT-302 in combination with Ranibizumab vs Ranibizumab alone in participants w/ nAMD
Eligibility:
- No prior treatment for nAMD
- Other protocol-specific inclusion and exclusion criteria may apply
Participants will:
- Have access to new treatment before the general public
- Be compensated for study visit
Principal Investigator: Sonia Dhoot, MD
Sub Investigator: Brian Kim, MD
Ocular Surface: Dry Eye Syndrome
Sponsor: Sight Sciences
Prospective, Randomized, Masked, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare® System in the Treatment of the Signs and Symptoms of Dry Eye Disease.
Purpose: To demonstrate the safety and effectiveness of TearCare® treatment compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
Eligibility:
● At least 22 years of age
● Reports dry eye symptoms within the past 3 to 6 months
● Other protocol-specific inclusion and exclusion criteria may apply
Participants will:
● Have access to new treatment before the general public
● Be compensated for study visit
Principal Investigator: John Hovanesian, MD
Sub Investigators: Isabell Choi, OD
Cataract Surgery: Lens Implementation
Sponsor: Alcon ICF
Post Approval Study of the AcrySof Ⓡ IQ AcrySof Ⓡ Toric IOLs.
Purpose: Cohort 2: Already an FDA-approved device, this study is focused on intraocular inflammation after implantation of ReSTOR Toric IOL in patients.
Eligibility:
- Planned cataract implantation
- Other protocol-specific inclusion and exclusion criteria may apply
Participants will:
- Receive complimentary premium IOL lens
- Be compensated for study visit
Principal Investigator: John Hovanesian, MD
Presbyopia
Sponsor: Novartis Pharmaceuticals
Title: Study of safety and efficacy of UNR844 in subjects with presbyopia.
Purpose: To determine the optimum dose of UNR844 treatment and duration of effect of UNR844 treatment for further development.
Eligibility:
- Ages 45 – 55
- No prior eye surgery (ie. LASIK, cataract surgery, etc.)
- Other protocol-specific inclusion and exclusion criteria may apply
Participants will:
- Have access to new treatment before the general public
- Be compensated for study visit
Principal Investigator: John Hovanesian, MD
Sub Investigators: Isabell Choi-Siritaratiwat, OD
Retina: Dry Age-Related Macular Degeneration
Sponsor: OnPoint Vision Inc – www.onpoint-vision.com
Early Feasibility Study to Evaluate the Safety and Effectiveness of the IOPCL AMD for Secondary Implantation in Capsular Bag to Improve Near Vision in Subjects with Age-Related Macular Degeneration after Cataract Surgery
Purpose:
To determine if the intraocular pseudophakic contact lens (IOPCL) referred to as the AccuraSee improves uncorrected near vision in subjects with dry age-related macular degeneration when previously implanted with a Alcon model SN60WF, SA60AT or SA60WF monocular intraocular lens (PCIOL).
Eligibility:
- 55 years or older of any sex
- Documented diagnosis of Dry Age-Related Macular Degeneration with Cataract surgery at least 6-months ago with either a Model SN60WF, SA60AT or SA60WF Alcon intraocular lens.
- Other protocol-specific inclusion and exclusion criteria may apply
Participants will:
- Have access to new treatment before the general public
- Be compensated for study visit
Principal Investigator: John Hovanesian, MD
Sub Investigator: Brian Kim, MD
Glaucoma Treatment
Sponsor: University of Pittsburg
CLARIFYING THE OPTIMAL APPLICATION OF SLT THERAPY (COAST)
Purpose:
Part 1: To compare the efficacy and safety of standard vs. low energy SLT in OHT or mild-moderate OAG.
Part 2: To determine the optimal interval and energy for repeat SLT (PRN at initial assignment vs. annually at low energy)
Eligibility:
- Newly diagnosed with ocular hypertension, mild, or moderate primary open-angle glaucoma
- No prior treatment for glaucoma
- Best-corrected vision 20/200 in both eyes
Participants will:
- Be compensated for study visit
Principal Investigator: Ye Elaine Wang, MD
Dry Age-Related Macular Edema
Sponsor: CLOVER Therapeutics
A decentralized epidemiological study of the progression of Age-related Macular Degeneration (AMD)
Purpose:
This is an epidemiologic study to identify genetic variants that slow down or prevent the clinical progression of intermediate AMD through advanced AMD.
Eligibility:
• Current patients (been seeing our providers for at least the past 3 years) diagnosed with intermediate or advanced AMD
Principal Investigator: Sonia B. Dhoot, MD
Sub-Investigator: Brian Kim, MD
FAQS
What is a clinical trial?
A clinical trial is a research study focused on evaluating the safety and efficacy of new medical treatments. Treatments can include new medical drugs, new combinations of drugs, new medical devices or surgical procedures, or new medical approaches.
Why should I participate in a clinical trial?
Participating in clinical trials is important in contributing to improving and developing new medical treatments for the future. Additionally, the studies can help progress science and overall improve the health and wellbeing of others. Participants in the studies not only aid others, but may also receive the newest treatments before the general public.
Which trial can I participate in?
Your doctor can help determine which clinical trial is right for you. They may refer you to a clinical research coordinator who can offer more information about the research studies that are available and suitable for your conditions.
Is there a cost to participate in a study?
There is no cost to participate in a clinical research study. As a research study participant, you may be eligible to receive a new treatment drug or device for free as well as compensation for your time in the study.
